| Literature DB >> 35878250 |
Ekaterina Georgieva1,2,3, Krasimira Benkova2, Nadya Vlaeva2, Yanka Karamalakova3, Radostina Miteva1, Hristo Abrashev4, Galina Nikolova3.
Abstract
Among the groups of users of illicit substances, a high percentage are persons deprived of their liberty; at the same time, each social and age group is also affected, to one degree or another. The purpose of this study is to provide general data on the relationship between different psychostimulants, clinical and socio-demographic studies, and gender, both among the general population and in one of the most at-risk groups. This review identifies the use of illicit substances as gender-specific in the general population. A detailed study of the causal relationship between the use of illicit substances and gender was carried out. Electronic databases Academic Search Complete, PubMed, HealthCare, Web of Science, and Google Scholar were searched for relevant studies up to 2022 associated with drug abuse and mental and health disorders. The analysis indicated that the human population showed significant differences between the sex of the consumer as to the type of drug consumers, development of addiction, and relapse. We focus on the pathological changes caused by drug use, the personal and physiological individual traits that influence drug choice, and the extent of use in one of the most affected groups of individuals. The study may provide some guidance in developing gender-specific treatment and prevention, including response to some pharmacological and behavioral therapies. The review is intended for a wide audience of social workers, toxicologists, and pharmacologists.Entities:
Keywords: addiction; drug abuse; gender biology; neurotransmitter; vulnerable population
Year: 2022 PMID: 35878250 PMCID: PMC9323370 DOI: 10.3390/toxics10070344
Source DB: PubMed Journal: Toxics ISSN: 2305-6304
Figure 1Comprehensive literature search strategy according to the chosen topic: inclusion and exclusion criteria.
Figure 2Model of drug addiction mechanism and dopamine projection in mesolimbic dopamine system: dopamine, drugs (stimulants, opioids), dopamine receptors, dopamine transporter (DAT). A schematic diagram illustrates the mesolimbic dopamine system in the brain and the dopamine neuronal role in drug addiction. Dopamine projections target the nucleus accumbens, prefrontal cortex, amygdala, and hippocampus. Direct administration of drugs and their systemic administration results in the release of large amounts of dopamine from dopamine neurons in the VTA, which is released into the nucleus accumbens and prefrontal cortex [77]. Reprinted with permission from Ref. [77]. 2021, NIDA Public Inquiries Team.
Data trend of illicit substances use in general population for according to World Drug Report 2019: large decrease in use drug type is reported for Greece, Latvia, and Lithuania for 2019 (*); large decrease in use drug type is reported for Ukraine for 2019 (**) [101].
| Regions | Drug Type | Trend |
|---|---|---|
| Western and Central Europe | Cannabis | Large increase/large decrease * |
| Cocaine | Large increase | |
| ATS | Large increase/large decrease * | |
| Opioids | Large increase | |
| Heroin | Large increase | |
| Hallucinogens | Large increase/large decrease * | |
| LSD | Large increase | |
| Southeastern Europe | Cannabis | No data |
| Cocaine | No data | |
| ATS | No data | |
| Opioids | No great change | |
| Heroin | No data | |
| Hallucinogens | No great change | |
| LSD | No great change | |
| Eastern Europe | Cannabis | No data |
| Cocaine | No great change | |
| ATS | No great change | |
| Opioids | No great change | |
| Heroin | No great change | |
| Hallucinogens | Large decrease ** | |
| LSD | Large decrease ** |
World data on drug abuse by sex or gender according to National Center for Drug Abuse Statistics in population aged 15–64 [108].
| Drug Abuse | Man, % | Woman, % |
|---|---|---|
| Opioids | 4 | 3.5 |
| Heroin | 0.5 | 0.2 |
| Cocaine | 2.6 | 1.5 |
| Cannabis | 18.5 | 13.5 |
| Methamphetamines | 0.8 | 0.4 |
| Misuse prescription pain killer pills | 3.9 | 3.4 |
| Misuse prescription tranquilants | 2.2 | 2.0 |
| Misuse prescription sedatives | 0.5 | 0.5 |
The data on drug abuse by sex or gender during 2018, according to Statistical Annex of United Nations Office on Drugs and Crime in population aged 15–64 in some European countries [108].
| Man, % | Woman, % | |
|---|---|---|
| COUNTRY | Cannabis | |
| Estonia | 9.20 | 4.81 |
| Finland | 11.20 | 5.20 |
| Germany | 8.87 | 5.25 |
| Netherlands | 13.90 | 6.30 |
| Norway | 7.00 | 3.70 |
| United Kingdom (England and Wales) | 10.28 | 5.00 |
| Cocaine | ||
| Estonia | 1.32 | 0.83 |
| Finland | 1.40 | 0.50 |
| Germany | 1.41 | 0.82 |
| Netherlands | 2.70 | 1.30 |
| Norway | 2.10 | 0.20 |
| United Kingdom (England and Wales) | 4.10 | 1.76 |
| Amphetamine and Methamphetamine | ||
| Estonia | 1.65 | 0.45 |
| Finland | 2.50 | 0.90 |
| Germany | 1.50 | 0.90 |
| Netherlands | 1.80 | 0.90 |
| Norway | 1.10 | 0.10 |
| United Kingdom (England and Wales) | 0.76 | 0.39 |
| Illicit opioids ●/Prescription opioids ●● | ||
| Estonia | 0.33● /0.22 ●● | 0.08● /0.08 ●● |
| Finland | 0.90 ●● | 0.80 ●● |
| Germany | 0.48 ● | 0.39 ●● |
| Netherlands | No data | No data |
| Norway | No data | No data |
| United Kingdom (England and Wales) | No data/0.07 ●● | No data/0.04 ●● |
| Barbiturates and Benzodiazepines | ||
| Estonia | 0.88 | 0.23 |
| Finland | No data | No data |
| Germany | No data | No data |
| Netherlands | 7.00 | 13.30 |
| Norway | No data | No data |
| United Kingdom (England and Wales) | 0.57 | 0.23 |